1. Neutralization of IFN-γ with emapalumab can reverse severe, refractory hemophagocytic lymphohistiocytosis.
2. Neutralizing IFN-γ did not impair control of multiple viral and other infections in a severely ill patient.
3. A 20 month old boy with acute EBV infection and HLH was successfully treated under an emergency investigational new drug application with the investigational agent emapalumab, despite severe preexisting comorbidities, including multiple life-threatening infections.
The article is generally trustworthy and reliable as it provides detailed information on the case study of a 20 month old boy with acute EBV infection and HLH who was successfully treated under an emergency investigational new drug application with the investigational agent emapalumab, despite severe preexisting comorbidities, including multiple life-threatening infections. The article also provides evidence for its claims by citing relevant studies and providing data from clinical laboratories. Furthermore, the article does not appear to be biased or one-sided as it presents both sides of the argument equally. However, there are some points that could be explored further such as potential risks associated with using emapalumab as a treatment for HLH and possible counterarguments to the findings presented in this article. Additionally, there is no mention of any promotional content in this article which suggests that it is unbiased and objective in its reporting.